Intratumoural spatial distribution of S100B + folliculostellate cells is associated with proliferation and expression of FSH and ERα in gonadotroph tumours.


Journal

Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673

Informations de publication

Date de publication:
09 02 2022
Historique:
received: 29 11 2021
accepted: 24 01 2022
entrez: 10 2 2022
pubmed: 11 2 2022
medline: 8 3 2022
Statut: epublish

Résumé

Folliculostellate cells are S100B-expressing cells with numerous functions in the normal anterior pituitary. These cells have also been identified in pituitary neuroendocrine tumours (PitNETs), where their precise role remains elusive. Here, we aimed to build a refined cartography of S100B-expressing cells to characterise their interpatient and intratumoural spatial distribution, and to start identifying their potential functions in PitNETs. High-throughput histological analysis of S100B-stained tumour sections of 54 PitNETs revealed a significant decrease in S100B + cells in PitNETs compared to the normal anterior pituitary. A Ki67 index ≥ 3, a mitosis count > 2/10 per high power fields, and a proliferative status, were all associated with fewer S100B + cells in gonadotroph tumours. Gonadotroph tumours also showed interpatient and intratumoural heterogeneity in the spatial distribution of S100B + cells. The existence of an intratumoural heterogeneity was further confirmed by the incorporation to our spatial analysis of additional markers: Ki67, FSH, LH, ERα and SSTR2. The tumour areas with fewer S100B + cells displayed a higher percentage of Ki67 + cells, whereas strong positive correlations were observed between S100B + , FSH + , and ERα + cells. Such spatial associations suggest that S100B + folliculostellate cells could play a role in gonadotroph tumorigenesis, and may contribute to the maintenance of tumour cells in a low proliferating, FSH + /ERα + differentiated state. Albeit, further in-depth functional studies are required to decipher the mechanisms underlying these spatial associations and to potentially identify a therapeutic use.

Identifiants

pubmed: 35139928
doi: 10.1186/s40478-022-01321-y
pii: 10.1186/s40478-022-01321-y
pmc: PMC8827287
doi:

Substances chimiques

Biomarkers, Tumor 0
ESR1 protein, human 0
Estrogen Receptor alpha 0
S100 Calcium Binding Protein beta Subunit 0
S100B protein, human 0
Follicle Stimulating Hormone 9002-68-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18

Informations de copyright

© 2022. The Author(s).

Références

Neuropathol Appl Neurobiol. 2021 Apr;47(3):415-427
pubmed: 33128255
J Clin Endocrinol Metab. 1994 Jun;78(6):1497-504
pubmed: 7515390
Ann Anat. 2013 May;195(3):231-7
pubmed: 23295121
Endocr Pathol. 2015 Dec;26(4):349-55
pubmed: 26481628
J Clin Endocrinol Metab. 2020 Oct 1;105(10):
pubmed: 32735647
Expert Rev Endocrinol Metab. 2016 Mar;11(2):149-162
pubmed: 30058871
J Neuroendocrinol. 2008 Jan;20(1):1-70
pubmed: 18081553
Exp Mol Med. 2018 Jan 5;50(1):e416
pubmed: 29303512
Nat Rev Endocrinol. 2021 Nov;17(11):671-684
pubmed: 34493834
Domest Anim Endocrinol. 1998 Sep;15(5):353-62
pubmed: 9785039
Mol Cell Endocrinol. 2012 Aug 15;359(1-2):43-52
pubmed: 22330643
Acta Neuropathol. 1984;65(1):35-40
pubmed: 6516800
Transl Oncol. 2017 Dec;10(6):956-975
pubmed: 29078205
J Neuroendocrinol. 1995 Jun;7(6):467-74
pubmed: 7550294
J Neuroendocrinol. 2008 Jun;20(6):687-91
pubmed: 18601690
Tissue Cell. 2017 Feb;49(1):78-85
pubmed: 27884532
Acta Neuropathol. 1986;71(3-4):233-42
pubmed: 3026133
Cancer Lett. 2015 Nov 1;368(1):7-13
pubmed: 26276713
Cell Mol Life Sci. 2015 Aug;72(15):2911-28
pubmed: 26084873
Eur J Endocrinol. 2005 Jul;153(1):1-12
pubmed: 15994739
J Clin Endocrinol Metab. 1998 Nov;83(11):3965-72
pubmed: 9814476
N Engl J Med. 2020 Mar 5;382(10):937-950
pubmed: 32130815
Cancers (Basel). 2020 Apr 20;12(4):
pubmed: 32326042
Acta Neuropathol. 2013 Jul;126(1):123-35
pubmed: 23400299
Hum Pathol. 2021 Aug;114:1-8
pubmed: 33991528
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3368-3374
pubmed: 28651368
Cancers (Basel). 2019 Oct 21;11(10):
pubmed: 31640258
Diagn Pathol. 2007 Jun 27;2:20
pubmed: 17597515
Front Neuroendocrinol. 2020 Jul;58:100852
pubmed: 32553750
Oncotarget. 2017 Jan 17;8(3):4690-4702
pubmed: 27902467
Brain Res. 1980 Jun 9;191(2):523-31
pubmed: 6991054
Biochem Biophys Res Commun. 1986 Mar 28;135(3):950-6
pubmed: 3083816
Pituitary. 2018 Apr;21(2):176-182
pubmed: 29288467
Endocr Relat Cancer. 2017 Apr;24(4):C5-C8
pubmed: 28264912
Virchows Arch. 1994;424(1):75-82
pubmed: 7981907
J Neurosurg. 2015 Apr;122(4):803-11
pubmed: 25658782
Pathol Res Pract. 1999;195(3):143-7
pubmed: 10220793
Cancer Cell. 2020 Jan 13;37(1):123-134.e5
pubmed: 31883967
Eur J Endocrinol. 2018 Jan;178(1):G1-G24
pubmed: 29046323
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2473-2489
pubmed: 30020466
Eur J Endocrinol. 2018 Mar;178(3):265-276
pubmed: 29330228
Virchows Arch. 2019 Dec;475(6):687-692
pubmed: 31578606
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8891-6
pubmed: 11438713
Cell. 2000 Dec 8;103(6):843-52
pubmed: 11136970
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32421791
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197

Auteurs

Mirela Diana Ilie (MD)

Inserm U1052, CNRS UMR5286, University Claude Bernard Lyon 1, Cancer Research Center of Lyon, Lyon, France.
Endocrinology Department, "C.I. Parhon" National Institute of Endocrinology, Bucharest, Romania.

Alexandre Vasiljevic (A)

Inserm U1052, CNRS UMR5286, University Claude Bernard Lyon 1, Cancer Research Center of Lyon, Lyon, France.
Pathology Department, Reference Center for Rare Pituitary Diseases HYPO, "Groupement Hospitalier Est" Hospices Civils de Lyon, Bron, France.

Marie Chanal (M)

Inserm U1052, CNRS UMR5286, University Claude Bernard Lyon 1, Cancer Research Center of Lyon, Lyon, France.

Nicolas Gadot (N)

Inserm U1052, CNRS UMR5286, University Claude Bernard Lyon 1, Cancer Research Center of Lyon, Lyon, France.
Pathology Research Platform, Department of Translational Research and Innovation, Centre Leon Berard, Lyon, France.

Laura Chinezu (L)

Pathology Department, Targu Mures Emergency Hospital, Targu Mures, Romania.
Histology Department, Pharmacy, Science and Technology of Targu Mures, University of Medicine, Targu Mures, Romania.

Emmanuel Jouanneau (E)

Inserm U1052, CNRS UMR5286, University Claude Bernard Lyon 1, Cancer Research Center of Lyon, Lyon, France.
Neurosurgery Department, Reference Center for Rare Pituitary Diseases HYPO, "Groupement Hospitalier Est" Hospices Civils de Lyon, Bron, France.

Ana Hennino (A)

Inserm U1052, CNRS UMR5286, University Claude Bernard Lyon 1, Cancer Research Center of Lyon, Lyon, France.

Gérald Raverot (G)

Inserm U1052, CNRS UMR5286, University Claude Bernard Lyon 1, Cancer Research Center of Lyon, Lyon, France.
Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, Groupement Hospitalier Est" Hospices Civils de Lyon, Bron, France.

Philippe Bertolino (P)

Inserm U1052, CNRS UMR5286, University Claude Bernard Lyon 1, Cancer Research Center of Lyon, Lyon, France. philippe.bertolino@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH